CAR T Cells: Second-Line Treatment Option for NHL? - NCI
4.6 (153) · $ 6.99 · In stock
Recent trial results suggest that CAR T cells may be superior to standard treatments for B-cell NHL that has not responded or has returned after treatment.
Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
Cancers, Free Full-Text
Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
media.springernature.com/m685/springer-static/imag
Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma - ScienceDirect
CAR T Therapy Fact Sheet by Brad Snyder - Issuu
Long-term safety and efficacy of CART-20 cells in patients with refractory or relapsed B-cell non-Hodgkin lymphoma: 5-years follow-up results of the phase I and IIa trials
Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and
Driving the next wave of innovation in CAR T-cell therapies
Cureus, Relapsed/Refractory Non-Hodgkin Lymphoma: Engineering T-Cells to Express Chimeric Antigen Receptors (CARs), a Salvage?
Cancers, Free Full-Text
What is CAR-T cell therapy? - Personalize My Medicine
CAR T-Cell Therapy Benefits Patients with Relapsed NHL
Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma
Frontiers Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL
